OPKO Health (OPK) just closed out FY 2025 with Q4 revenue of US$148.45 million, basic EPS of a US$0.04 loss, and quarterly net income excluding extra items showing a loss of US$31.26 million, set against trailing twelve month revenue of US$606.88 million and a loss of US$225.68 million on the same basis. The company has seen quarterly revenue move from US$183.64 million and basic EPS of US$0.02 in Q4 2024 to US$148.45 million and basic EPS of a US$0.04 loss in Q4 2025, while trailing twelve month basic EPS shifted from a US$0.08 loss in Q4 2024 to a US$0.30 loss in Q4 2025. With revenue edging forward on a trailing basis but losses still weighing on the P&L, the latest numbers keep the focus firmly on whether OPKO can eventually turn modest top line progress into more efficient margins.

See our full analysis for OPKO Health.

With the headline figures on the table, the next step is to see how these results line up with the widely held narratives about OPKO's growth potential, risk profile, and long term profitability story.

Losses widen on a US$225.7 million trailing basis

• On a trailing twelve month basis, OPKO reported revenue of US$606.9 million and a net loss excluding extra items of US$225.7 million, with trailing basic EPS at a loss of US$0.30 compared with a US$0.08 loss at the end of FY 2024.
• Consensus narrative points to ongoing pressure on profitability, and these figures line up with that:
  • Over the last 12 months, revenue growth of 2.7% per year sits well below the 10.3% per year growth forecast for the broader US market, while losses have grown at an annualized rate of 24.6% over the past five years.
  • Forecasts in the provided data indicate OPKO is expected to remain unprofitable over the next three years, so the trailing loss of US$225.7 million keeps the focus on whether the business can shift from relying on asset sales and R&D spending toward more consistent operating cash generation.

Premium P/S of 1.5x despite slow 2.7% revenue growth

• The shares trade on a P/S of 1.5x, above both the US healthcare industry average of 1.3x and peer average of 1.3x, even though revenue growth over the last 12 months is reported at 2.7% per year.
• Bears argue that paying above peer multiples is hard to justify while losses persist, and the current data gives them support:
  • Trailing twelve month net income excluding extra items is a loss of US$225.7 million, and analysts in the cautious view do not expect profitability over the next three years, which means there is no P/E support and investors are leaning on sales and future margin hopes.
  • At a share price of US$1.20, the analyst consensus price target of US$3.53 implies a large price gap, yet the need for a 105.5x P/E in 2028 in that scenario underlines how much of the case depends on a shift from the current loss making profile.

Investors who see this premium P/S as an early sign of a turnaround story rather than a red flag may want to read how bulls frame OPKO's pipeline and partnerships in more detail: 🐂 OPKO Health Bull Case

DCF fair value of US$5.25 versus US$1.20 share price

• The provided DCF fair value is US$5.25 per share compared with the current share price of US$1.20, which means the stock is trading about 77.1% below that model based estimate.
• Supporters of the bullish narrative lean heavily on this gap to argue for upside, but the numbers also show where the case is demanding:
  • For analyst scenarios to work, the company would need revenue to reach the hundreds of millions in 2028 with earnings in the US$35.5 million to US$43.9 million range, starting from a trailing loss of US$177.1 million in the data, which represents a very large swing in profitability.
  • Even in the more cautious analyst setup, this would require OPKO to trade on a future P/E that is several times higher than the current US healthcare industry average, so anyone relying on the DCF fair value needs to be comfortable with both the growth and margin assumptions sitting behind that US$5.25 figure.

If you are trying to weigh that DCF fair value against the current loss profile and premium P/S, it can help to see how skeptics frame the downside risks and what would need to go right for OPKO: 🐻 OPKO Health Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for OPKO Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of pressure and potential leaves you unsure, take action while the data is fresh and weigh it against 1 key reward and 1 important warning sign.

Explore Alternatives

OPKO is carrying a trailing loss of US$225.7 million, widening EPS losses and a premium 1.5x P/S, which leaves profitability and valuation under clear pressure.

If those widening losses and the gap between price and earnings targets feel uncomfortable, shift your focus toward 76 resilient stocks with low risk scores that could offer a calmer ride for your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.